Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

AJAlexandria JensenDLDasom LeeAGAnmol Goyal

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows cutpoint for metabolic tumor volume predicts patient outcomes in R/R LBCL, indicating treatment response and safety assessments.

Key Points

  • High metabolic tumor volume is associated with worse progression-free survival in relapsed/refractory large B cell lymphoma.
  • Median progression-free survival was significantly different, with high tumor volume showing 4.2 months versus 36.3 months in low volume patients.
  • Analysis utilized logistic regression to examine treatment response while also monitoring patient safety assessments over 39.5 months.
  • Findings suggest a clear cutpoint to help identify high-risk patients requiring more intensive treatment options.

Cite This Study

Jensen et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d736https://doi.org/10.1182/blood-2025-397
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognosis prediction beyond MTV using easy to calculate parameters derived from FDG-PET/CT, a pilot Study2025
  2. 2Performance of radiomics features in patients with peripheral T-cell lymphoma: Data from international prospective T-cell project 2.02025
  3. 3Total metabolic tumor volume as a prognostic biomarker in high-burden follicular lymphoma: A systematic review and meta-analysis2025
  4. 4Baseline PET-CT in predicting CRS and survival outcomes of R/R MM patients following CAR T-cell therapy2025
  5. 5Analysis of the role of baseline PET/CT in a prospective study of unselected patients: The UK MCL biobank2025